Prudential Financial
TRVI icon

Prudential Financial’s Trevi Therapeutics TRVI Stock Holding History

Prudential Financial’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
17,411
+2,685
+18% +$39K ﹤0.01% 2078
2026
Q1 		$176K Sell
14,726
-534,493
-97% -$5.98M ﹤0.01% 2163
2025
Q4 		$6.88M Sell
549,219
-53,435
-9% -$618K 0.01% 783
2025
Q3 		$5.51M Buy
602,654
+376,273
+166% +$2.82M 0.01% 871
2025
Q2 		$1.24M Buy
+226,381
New +$1.41M ﹤0.01% 1582

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Prudential Financial's TRVI Position: Q2 2026 in Review

Prudential Financial increased its Trevi Therapeutics (TRVI) stake by 18% in Q2 2026, buying an estimated $39K and bringing the position to 17,411 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Prudential Financial first reported a position in TRVI in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.88M in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Prudential Financial held 17,411 shares of Trevi Therapeutics worth $325K as of Q2 2026.
  • Prudential Financial bought 2,685 Trevi Therapeutics shares in Q2 2026, an estimated $39K.
  • Trevi Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2078 holding.
  • Prudential Financial first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Prudential Financial's Trevi Therapeutics position peaked at $6.88M in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.